Drug policy 101: Breaking down different types of drug products

  • October 22, 2019

As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is important for policymakers to understand the distinct differences between broad categories of therapies as they examine potential solutions.

Drug policy 101: The state of the pharmaceutical evidence base

  • September 26, 2019

Having sound evidence about a drug’s safety and effectiveness is critical to understanding its benefits and value. In recent years, shifts in the pharmaceutical evidence base have created challenges for evaluating drugs after they come to market.

Drug policy 101: Drug patents

  • July 31, 2019

As drug prices continue rising unsustainably in the United States, patients and payers need to understand — and policy makers need to address — how pharmaceutical companies use patents to maintain monopolies and pricing power.

Drug policy 101: Biosimilars

  • January 1, 2019

Biologics — drugs derived from living organisms that are used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and some cancers — are the fastest growing component of prescription drug spending.

Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)

  • November 1, 2018

Over the past couple of decades, pharmaceutical innovation has provided many new treatments for diseases that previously had limited therapeutic options. However, some of these specialty treatments have well documented side effects (known as adverse events) that must be carefully…

Drug Policy 101: Pay-for-delay

  • April 1, 2018

The term “pay-for-delay” refers to a tactic used by brand name drug manufacturers to delay a potential competitor from bringing a generic drug alternative to market. Usually in the form of a cash payment, pay-for-delay transactions result from a patent…